Study Extends Potential of Personalized Cell-based Immunotherapies
News Mar 16, 2018 | Original story from Ludwig Institute for Cancer Research

Shown here is a pseudo-colored scanning electron micrograph of an oral squamous cancer cell (white) being attacked by two cytotoxic T cells (red), part of a natural immune response. Credit: Rita Elena Serda, NCI/Duncan Comprehensive Cancer Center at Baylor College of Medicine
A Ludwig Cancer Research study shows that ovarian cancer, which has proved resistant to currently available immunotherapies, could be susceptible to personalized immunotherapy. Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne, the study shows that ovarian tumors harbor highly reactive killer T cells—which kill infected and cancerous cells—and demonstrates how they can be identified and selectively grown for use in personalized, cell-based immunotherapies.
“Tumors whose cells tend to be highly mutated, like those of melanoma and lung cancer, are the ones that respond best to immunotherapies,” says Harari. “It has long been a question whether we’d even be able to detect sufficiently mutation-reactive T cells in patients with tumors that have low mutational loads.”
Harari, Coukos and their colleagues report in Nature Communications that, despite their low mutational load, epithelial ovarian tumors are infiltrated with T cells that are especially good at recognizing and killing cancer cells.
Cancer cells that have a relatively large number of mutations in their DNA express aberrant proteins—or neoantigens—that reveal the cancer to the immune system. Killer T cells recognize tiny, mutated bits of these antigens, known as neoepitopes. But neoepitopes vary wildly from patient to patient, even within the same type of cancer. This has long stymied efforts to develop generally effective therapies that target cancer antigens.
To get around this problem, researchers have been developing sophisticated methods to extract T cells from patients, select and expand those that best target a patient’s cancer and reinfuse them into the patient. These approaches usually rely on T cells extracted from the bloodstream, not those already inside the tumor, which are referred to as TILs (for tumor infiltrating lymphocytes).
Experimental therapies using T cells taken from the blood stream have not, however, worked very well against solid tumors. Further, when TILs have been used for such purposes, the proportion of what Harari calls the “juiciest” T cells—those recognizing mutations on cancer cells—tends to decline significantly when the cells are expanded in culture.
“To circumvent these problems, we developed a new methodology to identify highly reactive TILs and expand them in a manner that, rather than diluting the juiciest TILs, enriches them instead,” says Harari. “This allowed us to compare the activity of TILs that target neoepitopes with their counterparts in the peripheral bloodstream.”
The researchers show that killer T cells isolated from ovarian tumors using their method are much better at both recognizing neoepitopes than are those isolated from blood.
“We could even compare T cells from the two compartments targeting the exact same mutation and show that the TILs were more functional than the T cells we collected from the peripheral bloodstream,” says Harari.
Notably, the researchers found that, using their methods, highly reactive TILs could be obtained from some 90% of the ovarian cancer patients whose tumor samples they examined.
“The big message,” says Coukos, “is that future cell-based therapies can be envisioned for low mutational load tumors and should prioritize the use of TILs over T cells collected from peripheral blood. This novel strategy to obtain enriched TILs also offers great therapeutic opportunities.”
Harari, Coukos and their colleagues will now be applying their findings to an ambitious program to develop and streamline personalized immunotherapies for cancer patients currently underway at the Lausanne Branch of the Ludwig Institute for Cancer Research
This article has been republished from materials provided by Ludwig Institute for Cancer Research. Note: material may have been edited for length and content. For further information, please contact the cited source.
RELATED ARTICLES
Sweet Spot of Activity in Immune System Key to Fighting Cancer
NewsScientists have shown how stimulating a specific location on the surface of immune cells can be targeted with antibodies to help in their fight against cancer.
READ MORESheep Toxin Could Cause MS
NewsExposure to a toxin primarily found in sheep could be linked to the development of multiple sclerosis (MS) in humans, new research suggests.
READ MORECompound Offers Pain-relief of Opioids Without Addictive Properties
NewsResearchers have engineered a new compound that animal tests suggest could offer the pain-relieving properties of opioids such as morphine and oxycodone without the risk of addiction.
READ MOREComments | 0 ADD COMMENT
Like what you just read? You can find similar content on the communities below.
Biopharma Cancer Research Drug DiscoveryTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
Login
You must be logged in to post a comment.